Last reviewed · How we verify
Standard anticoagulation
Standard anticoagulation prevents blood clot formation by inhibiting coagulation cascade factors, reducing thrombotic events.
Standard anticoagulation prevents blood clot formation by inhibiting coagulation cascade factors, reducing thrombotic events. Used for Venous thromboembolism prophylaxis and treatment, Atrial fibrillation for stroke prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Standard anticoagulation |
|---|---|
| Sponsor | Faculty Hospital Kralovske Vinohrady |
| Drug class | Anticoagulant |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Standard anticoagulation typically refers to conventional anticoagulants such as warfarin (vitamin K antagonist) or unfractionated heparin, which work by inhibiting key factors in the coagulation cascade. Warfarin inhibits vitamin K-dependent factors (II, VII, IX, X), while heparin potentiates antithrombin III to inactivate factors IIa and Xa. These agents are used to prevent and treat thromboembolism across multiple clinical settings.
Approved indications
- Venous thromboembolism prophylaxis and treatment
- Atrial fibrillation for stroke prevention
- Mechanical heart valve thromboprophylaxis
- Acute coronary syndrome
Common side effects
- Bleeding
- Bruising
- Heparin-induced thrombocytopenia (HIT)
- Warfarin skin necrosis
Key clinical trials
- Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO (PHASE2)
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury (NA)
- Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation (NA)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- Effect of iNO in Patients With Submassive and Massive PE (PHASE2)
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard anticoagulation CI brief — competitive landscape report
- Standard anticoagulation updates RSS · CI watch RSS
- Faculty Hospital Kralovske Vinohrady portfolio CI